Denali Therapeutics Inc. (DNLI)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Ryan J. Watts Ph.D.
|
Co-Founder, President, CEO & Director | 1.42M | 6.91M | 1976 |
|
Dr. Alexander O. Schuth M.D., Ph.D.
|
Co-Founder, CFO, COO & Secretary | 926.17k | -- | 1973 |
|
Dr. Dana Andersen
|
Chief Technical and Manufacturing Officer | -- | -- | -- |
|
Mr. Joe Lewcock Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Mr. Chris Walsh J.D.
|
General Counsel | -- | -- | -- |
|
Ms. Cindy Dunkle
|
Chief People Officer | -- | -- | -- |
|
Ms. Katie Peng M.B.A.
|
Chief Commercial Officer | -- | -- | 1971 |
|
Mr. Peter Chin M.D.
|
Acting Chief Medical Officer & Head of Development | -- | -- | 1968 |
Denali Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 503
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
November 3, 2026 at 8:00 PM UTC
Denali Therapeutics Inc. Earnings Date
